About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the ...

Merck , known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an ...

Kimberly-Clark Corporation today announced that Joseph Romanelli, president of Human Health International for Merck & Co., Inc., Rahway, NJ, USA, ("MSD") has been elected to its board of directors, ...

Stronger America Through Seafood (SATS), a coalition of stakeholders in the U.S. aquaculture industry, has launched a ...

The event’s largest edition yet, nearly doubling the 2023 size, with Hall A1 fully booked six months in advance analytica ...

As a significant milestone in India's pharma sector, the 17th edition of CPHI & PMEC India, organised by Informa Markets in India, returns in an advanced format, scheduled from November 26 to 28, 2024 ...

(Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechnology company focused on gastrointestinal diseases that was acquired by Merck for $10.8 billion in 2023. Prior ...

The protein expression technology market is projected to be worth USD 2,675.20 million in 2023. The market is likely to reach ...

The global protein expression market is expected to reach USD 4.82 billion in 2029 from USD 3.41 billion in 2024 at a CAGR of ...